Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KLOXXADO vs EVZIO (AUTOINJECTOR)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.
Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.
Reversal of conscious sedation induced by benzodiazepines,Management of benzodiazepine overdose,Off-label: reversal of benzodiazepine effects in hepatic encephalopathy
Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression
5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.
Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); clinical context: short half-life supports rapid reversal of opioid effects but requires monitoring for renarcotization, especially with long-acting opioids.
Terminal elimination half-life of naloxone is approximately 1–2 hours in adults. The short half-life results in a duration of action that may be shorter than that of the opioid (e.g., fentanyl, methadone), necessitating repeated doses or continuous infusion. In neonates, half-life is prolonged (3–4 hours).
Hepatic metabolism via CYP1A2 and CYP3A4; undergoes extensive first-pass metabolism; major metabolites are inactive or less active.
Primarily hepatic via glucuronidation; minor pathways include N-dealkylation. CYP450 involvement is minimal.
Hepatic metabolism primarily via CYP3A4 to inactive metabolites; renal excretion accounts for <1% of unchanged drug; fecal excretion accounts for approximately 50-60% of the dose as metabolites.
Naloxone is primarily metabolized in the liver via glucuronidation, with minor contributions from N-dealkylation. The metabolites (naloxone-3-glucuronide) and parent drug are excreted renally. Approximately 50% of a dose is excreted in urine as naloxone-3-glucuronide, 25% as unchanged naloxone (after IV), and <5% in feces. Biliary excretion is minimal (<1%).
Approximately 80% bound to plasma proteins, primarily albumin.
Approximately 45% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 2-4 L/kg; high Vd indicates extensive tissue distribution, which is consistent with rapid redistribution from brain to peripheral tissues, contributing to its short duration of action.
2–3 L/kg in adults. The large Vd indicates extensive tissue distribution, including crossing the blood-brain barrier rapidly to reverse central opioid effects. In neonates, Vd is higher (3–5 L/kg).
Intranasal bioavailability is approximately 40-50% relative to intravenous administration; gastrointestinal absorption is limited due to first-pass metabolism, so oral bioavailability is <1%.
Intramuscular or subcutaneous: approximately 60–80% relative to IV (with the autoinjector delivering 0.4 mg or 2 mg doses). Oral bioavailability is <2% due to extensive first-pass metabolism, making oral administration ineffective for opioid reversal; thus, the autoinjector is for IM/SC use only.
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); severe hepatic impairment (Child-Pugh C) has not been studied, use with caution.
No dose adjustment required for hepatic impairment.
Weight ≥30 kg: 5 mg intranasally as single dose; weight 10-30 kg: 2.5 mg intranasally as single dose; may repeat once after 2-3 minutes if needed.
Weight-based dosing: For children weighing <20 kg, 0.1 mg/kg intramuscularly or subcutaneously; for ≥20 kg, 2 mg intramuscularly or subcutaneously. Repeat every 2-3 minutes as needed.
No specific dose adjustment; elderly patients may be more sensitive to adverse effects, monitor for excessive sedation or respiratory depression.
No specific dose adjustment needed; use caution due to potential comorbidities.
None.
None.
Risk of seizures, especially in patients with physical dependence on benzodiazepines, concurrent tricyclic antidepressant overdose, or history of seizures,Do not use for diagnostic purposes in suspected seizure disorders,May cause panic attacks in patients with anxiety disorders,Monitor for resedation due to shorter duration of action than benzodiazepines
Risk of acute withdrawal syndrome in opioid-dependent patients.,May precipitate severe withdrawal in neonates if used during pregnancy.,Limited efficacy against buprenorphine or partial agonists; higher or repeat doses may be needed.,Monitor for recurrence of respiratory depression due to short duration of action relative to some opioids.,Not a substitute for emergency medical care.
Known hypersensitivity to flumazenil or benzodiazepines,Patients receiving benzodiazepines for control of life-threatening conditions (e.g., increased intracranial pressure, status epilepticus),Evidence of serious tricyclic antidepressant overdose
Hypersensitivity to naloxone or any component of the autoinjector.
No known food interactions with Kloxxado. Naloxone is not affected by food intake. Avoid alcohol or sedatives as they may exacerbate opioid effects.
No known food interactions with naloxone. No dietary restrictions required.
Pregnancy category D: Positive evidence of human fetal risk in first trimester (increased risk of oral clefts), second and third trimesters (risk of maternal and neonatal respiratory depression, neonatal withdrawal syndrome). Avoid in pregnancy unless benefit outweighs risk.
Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal malformations; may precipitate withdrawal in opioid-dependent fetuses, potentially causing fetal distress or preterm labor.
Excreted in breast milk; M/P ratio unknown. Potential for infant sedation and withdrawal. Use caution; consider alternative agents or monitor for drowsiness and feeding difficulties.
Naloxone is excreted in breast milk in trace amounts; no adverse effects reported in nursing infants. M/P ratio not available.
No standard dose adjustment recommended; however, pharmacokinetic changes (increased volume of distribution, altered clearance) may require higher or more frequent dosing to maintain efficacy. Individualize based on response and tolerance.
No pharmacokinetic data indicate dose adjustments; use same dose as non-pregnant adults. Reversal of opioid effects may precipitate withdrawal; monitor closely.
Kloxxado (naloxone) 8 mg nasal spray is FDA-approved for emergency treatment of opioid overdose. Use in patients with known or suspected opioid overdose, including respiratory depression. Onset within 2-3 minutes. May require repeat dosing due to shorter half-life than many opioids. Monitor for withdrawal precipitation. Store at room temperature; protect from light. Train caregivers and patients on proper administration.
EVZIO is a naloxone auto-injector for emergency treatment of opioid overdose. Administer intramuscularly or subcutaneously into anterolateral thigh (through clothing if necessary). Each device delivers a single 2 mg dose. After use, seek immediate medical attention due to short half-life (30-81 min) relative to opioids; repeated doses may be needed. Monitor for opioid withdrawal syndrome, especially in physically dependent patients. Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F). Do not remove the auto-injector from its case until ready to use.
Administer as soon as opioid overdose is suspected: unresponsiveness, slow/stopped breathing, or pin-point pupils.,Spray one dose into one nostril; if no response in 2-3 minutes, give second dose in other nostril using a new device.,Call 911 immediately before or after administration; Kloxxado is a temporary measure.,Stay with patient until emergency help arrives; repeat doses may be needed if opioids are long-acting (e.g., fentanyl).,Side effects include acute withdrawal symptoms (nausea, vomiting, sweating, agitation, rapid heart rate).,Store at 68-77°F (20-25°C); do not freeze. Check expiration date.
Inject EVZIO into the outer thigh, through clothing if needed, as soon as overdose is suspected.,After injecting, call 911 or seek emergency medical help immediately.,The effect of EVZIO lasts only 30-90 minutes; opioids may last longer, so repeated doses might be necessary.,Family and caregivers should receive training on recognizing overdose signs (unconsciousness, slow breathing, pinpoint pupils) and using EVZIO.,Store EVZIO in its case at room temperature, away from light and moisture; do not refrigerate or freeze.,Check expiration date regularly and replace before expiry; training devices are for practice only.,An overdose may cause withdrawal symptoms such as nausea, vomiting, sweating, rapid heart rate, or agitation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KLOXXADO vs EVZIO (AUTOINJECTOR), answered by our medical review team.
KLOXXADO is a Opioid Antagonist that works by KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.. EVZIO (AUTOINJECTOR) is a Opioid Antagonist that works by Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KLOXXADO and EVZIO (AUTOINJECTOR) depend on the specific clinical indication. These are both Opioid Antagonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KLOXXADO is: 5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.. The standard adult dose of EVZIO (AUTOINJECTOR) is: Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KLOXXADO and EVZIO (AUTOINJECTOR) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KLOXXADO is classified as Category C. Pregnancy category D: Positive evidence of human fetal risk in first trimester (increased risk of oral clefts), second and third trimesters (risk of maternal and neonatal respirato. EVZIO (AUTOINJECTOR) is classified as Category C. Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.